Clinical Study of Bivalirudin for Percutaneous Coronary Intervention (PCI)

Summary

Bivalirudin is widely used as an anticoagulant to reduce the risk of bleeding in PCI perioperative period. Additionally, 15.7%-32.7% patients have diabetes mellitus who undergo percutaneous coronary interventions (PCI), so bivalirudin was used to anticoagulate in these patients to evaluate its safety and efficacy.

Timeline

Start

2018-09-15

Primary completion

2019-08-12

Completion

2020-08-12

Drugs

Indications